Which MOA involves NO donating moiety?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

Which MOA involves NO donating moiety?

Explanation:
NO donating moieties in glaucoma meds are found in latanoprostene bunod. This drug blends a prostaglandin F receptor agonist component with a nitric oxide donor. The prostaglandin part lowers IOP by enhancing uveoscleral outflow, while the released nitric oxide relaxes the trabecular meshwork and Schlemm’s canal via activation of soluble guanylate cyclase, increasing conventional outflow. The other prostaglandin analogs raise IOP mainly through FP receptor–mediated effects on the uveoscleral pathway and do not include an NO-donor moiety. So the NO-donating mechanism is specific to latanoprostene bunod.

NO donating moieties in glaucoma meds are found in latanoprostene bunod. This drug blends a prostaglandin F receptor agonist component with a nitric oxide donor. The prostaglandin part lowers IOP by enhancing uveoscleral outflow, while the released nitric oxide relaxes the trabecular meshwork and Schlemm’s canal via activation of soluble guanylate cyclase, increasing conventional outflow. The other prostaglandin analogs raise IOP mainly through FP receptor–mediated effects on the uveoscleral pathway and do not include an NO-donor moiety. So the NO-donating mechanism is specific to latanoprostene bunod.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy